Coglapix Injektionsvätska, suspension Svezia - svedese - Läkemedelsverket (Medical Products Agency)

coglapix injektionsvätska, suspension

ceva santé animale - actinobacillus pleuropneumoniae, apxi-toxoid; actinobacillus pleuropneumoniae, apxii-toxoid; actinobacillus pleuropneumoniae, apxiii-toxoid - injektionsvätska, suspension - tiomersal hjälpämne; aluminiumoxid, hydratiserad adjuvans; actinobacillus pleuropneumoniae, apxi-toxoid 28,9 elisa e aktiv substans; actinobacillus pleuropneumoniae, apxii-toxoid 16,7 elisa e aktiv substans; actinobacillus pleuropneumoniae, apxiii-toxoid 6,8 elisa e aktiv substans - svin

Hyobac App 2 Vet. Injektionsvätska, emulsion Svezia - svedese - Läkemedelsverket (Medical Products Agency)

hyobac app 2 vet. injektionsvätska, emulsion

salfarm danmark a/s - actinobacillus pleuropneumoniae, apxii-toxoid; actinobacillus pleuropneumoniae, apxiii-toxoid; actinobacillus pleuropneumoniae, serotyp 2, stam wslb 3012, inaktiverad - injektionsvätska, emulsion - actinobacillus pleuropneumoniae, apxii-toxoid 0,25 - 2,5 mikrog aktiv substans; actinobacillus pleuropneumoniae, apxiii-toxoid 0,23 - 2,3 mikrog aktiv substans; emulsigen sa 0,2 ml adjuvans; actinobacillus pleuropneumoniae, serotyp 2, stam wslb 3012, inaktiverad 4200 - 42000 miljoner cfu aktiv substans; tiomersal hjälpämne - svin

Hyobac App Multi Vet. Injektionsvätska, emulsion Svezia - svedese - Läkemedelsverket (Medical Products Agency)

hyobac app multi vet. injektionsvätska, emulsion

salfarm danmark a/s - actinobacillus pleuropneumoniae, apxi-toxoid; actinobacillus pleuropneumoniae, apxii-toxoid; actinobacillus pleuropneumoniae, apxiii-toxoid; actinobacillus pleuropneumoniae, serotyp 2, stam wslb 3012, inaktiverad; actinobacillus pleuropneumoniae, serotyp 5, stam wslb 3079 / serotyp 6, stam wslb 3075, inaktiverad - injektionsvätska, emulsion - actinobacillus pleuropneumoniae, apxiii-toxoid 0,125 - 1,25 mikrog aktiv substans; actinobacillus pleuropneumoniae, apxii-toxoid 0,29 - 2,9 mikrog aktiv substans; actinobacillus pleuropneumoniae, apxi-toxoid 0,228 - 2,28 mikrog aktiv substans; actinobacillus pleuropneumoniae, serotyp 5, stam wslb 3079 / serotyp 6, stam wslb 3075, inaktiverad 1400 - 14000 miljoner cfu aktiv substans; actinobacillus pleuropneumoniae, serotyp 2, stam wslb 3012, inaktiverad 1400 - 14000 miljoner celler aktiv substans; emulsigen sa 0,2 ml adjuvans; tiomersal hjälpämne - svin

Scatol 3 mg Tablett Svezia - svedese - Läkemedelsverket (Medical Products Agency)

scatol 3 mg tablett

2care4 generics aps - ivermektin - tablett - 3 mg - ivermektin 3 mg aktiv substans; butylhydroxianisol hjälpämne

Porcilis M Hyo ID vet Injektionsvätska, emulsion Svezia - svedese - Läkemedelsverket (Medical Products Agency)

porcilis m hyo id vet injektionsvätska, emulsion

intervet international b.v. - mycoplasma hyopneumoniae, stam 11, inaktiverad - injektionsvätska, emulsion - paraffin, lättflytande 34,6 mg adjuvans; all-rac-alfa-tokoferylacetat 2,5 mg adjuvans; mycoplasma hyopneumoniae, stam 11, inaktiverad 6,5 log2 ab-enheter aktiv substans - svin

Mhyosphere PCV ID Unione Europea - svedese - EMA (European Medicines Agency)

mhyosphere pcv id

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - grisar - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Ivermectin Medical Valley 3 mg Tablett Svezia - svedese - Läkemedelsverket (Medical Products Agency)

ivermectin medical valley 3 mg tablett

medical valley invest ab - ivermektin - tablett - 3 mg - butylhydroxianisol hjälpämne; ivermektin 3 mg aktiv substans

Amiodaron hameln 50 mg/ml Koncentrat till injektions-/infusionsvätska, lösning Svezia - svedese - Läkemedelsverket (Medical Products Agency)

amiodaron hameln 50 mg/ml koncentrat till injektions-/infusionsvätska, lösning

hameln pharma gmbh - amiodaronhydroklorid - koncentrat till injektions-/infusionsvätska, lösning - 50 mg/ml - bensylalkohol hjälpämne; amiodaronhydroklorid 50 mg aktiv substans - amiodaron

Fludarabin Hospira 50 mg Pulver till injektions-/infusionsvätska, lösning Svezia - svedese - Läkemedelsverket (Medical Products Agency)

fludarabin hospira 50 mg pulver till injektions-/infusionsvätska, lösning

hospira uk limited - fludarabinfosfat - pulver till injektions-/infusionsvätska, lösning - 50 mg - mannitol hjälpämne; fludarabinfosfat 50 mg aktiv substans - fludarabin

Pulmotec Beredningssats för radioaktivt läkemedel Svezia - svedese - Läkemedelsverket (Medical Products Agency)

pulmotec beredningssats för radioaktivt läkemedel

cyclomedica ireland ltd - grafit - beredningssats för radioaktivt läkemedel - grafit 1,34 g aktiv substans - teknetium(tc-99m)teknegas